JP2022512629A5 - - Google Patents
Info
- Publication number
- JP2022512629A5 JP2022512629A5 JP2021518969A JP2021518969A JP2022512629A5 JP 2022512629 A5 JP2022512629 A5 JP 2022512629A5 JP 2021518969 A JP2021518969 A JP 2021518969A JP 2021518969 A JP2021518969 A JP 2021518969A JP 2022512629 A5 JP2022512629 A5 JP 2022512629A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid substitution
- index
- optionally
- region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025113503A JP2025160215A (ja) | 2018-10-23 | 2025-07-04 | Ｆｃサイレンス化抗体薬物コンジュゲート（ＡＤＣ）及びその使用 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862749662P | 2018-10-23 | 2018-10-23 | |
| US62/749,662 | 2018-10-23 | ||
| US201862773839P | 2018-11-30 | 2018-11-30 | |
| US62/773,839 | 2018-11-30 | ||
| US201962807363P | 2019-02-19 | 2019-02-19 | |
| US62/807,363 | 2019-02-19 | ||
| PCT/US2019/057741 WO2020086776A1 (en) | 2018-10-23 | 2019-10-23 | Fc silenced antibody drug conjugates (adcs) and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025113503A Division JP2025160215A (ja) | 2018-10-23 | 2025-07-04 | Ｆｃサイレンス化抗体薬物コンジュゲート（ＡＤＣ）及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022512629A JP2022512629A (ja) | 2022-02-07 |
| JP2022512629A5 true JP2022512629A5 (https=) | 2022-11-01 |
| JP7709376B2 JP7709376B2 (ja) | 2025-07-16 |
Family
ID=70331253
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021518969A Active JP7709376B2 (ja) | 2018-10-23 | 2019-10-23 | Ｆｃサイレンス化抗体薬物コンジュゲート（ＡＤＣ）及びその使用 |
| JP2025113503A Pending JP2025160215A (ja) | 2018-10-23 | 2025-07-04 | Ｆｃサイレンス化抗体薬物コンジュゲート（ＡＤＣ）及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025113503A Pending JP2025160215A (ja) | 2018-10-23 | 2025-07-04 | Ｆｃサイレンス化抗体薬物コンジュゲート（ＡＤＣ）及びその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20200255523A1 (https=) |
| EP (1) | EP3873930A4 (https=) |
| JP (2) | JP7709376B2 (https=) |
| KR (1) | KR20210081393A (https=) |
| CN (1) | CN113330026A (https=) |
| AU (1) | AU2019366960A1 (https=) |
| BR (1) | BR112021007555A2 (https=) |
| CA (1) | CA3115680A1 (https=) |
| CO (1) | CO2021006259A2 (https=) |
| IL (1) | IL282292A (https=) |
| MX (1) | MX2021004231A (https=) |
| SG (1) | SG11202103568PA (https=) |
| WO (1) | WO2020086776A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019265019B2 (en) | 2018-05-11 | 2025-11-06 | Beam Therapeutics Inc. | Methods of substituting pathogenic amino acids using programmable base editor systems |
| US20200376135A1 (en) * | 2018-10-23 | 2020-12-03 | Magenta Therapeutics, Inc. | Fc silenced antibody drug conjugates (adcs) and uses thereof |
| EP3877416A4 (en) | 2018-10-30 | 2022-07-27 | Magenta Therapeutics, Inc. | ANTI-CD45 ANTIBODIES AND CONJUGATES THEREOF |
| JP2022531141A (ja) * | 2019-04-24 | 2022-07-06 | マジェンタ セラピューティクス インコーポレイテッド | 遺伝子治療のコンディショニング方法 |
| EP3959242A4 (en) * | 2019-04-24 | 2023-09-13 | Magenta Therapeutics, Inc. | ANTRACYCLINE ANTIBODY-DRUG CONJUGATES AND THEIR USES |
| JP2022530443A (ja) * | 2019-04-24 | 2022-06-29 | マジェンタ セラピューティクス インコーポレイテッド | 抗ｃｄ１１７抗体薬物複合体およびその使用 |
| IL292628A (en) | 2019-11-01 | 2022-07-01 | Magenta Therapeutics Inc | Anti-cd45 antibody and conjugates accordingly |
| AU2021239929A1 (en) * | 2020-03-16 | 2022-10-13 | Crispr Therapeutics Ag | T-cell bispecific binding proteins |
| GB2595299B (en) | 2020-05-21 | 2022-08-03 | Mabsolve Ltd | Modified immunoglobulin FC regions |
| EP4161946A1 (en) | 2020-06-09 | 2023-04-12 | Heidelberg Pharma Research GmbH | Method for synthesis of thioether-containing peptides |
| WO2021255217A1 (en) | 2020-06-19 | 2021-12-23 | Heidelberg Pharma Research Gmbh | Amatoxin and amatoxin conjugates for use in inhibition of rna virus replication |
| KR20230152783A (ko) | 2020-07-07 | 2023-11-03 | 칸큐어 엘엘씨 | Mic 항체 및 결합제 및 이의 사용 방법 |
| KR20250054799A (ko) | 2022-08-29 | 2025-04-23 | 다이이찌 산쿄 가부시키가이샤 | 변이 Fc 영역을 포함하는 항체 약물 콘쥬게이트 |
| WO2024121632A1 (en) * | 2022-12-09 | 2024-06-13 | Crispr Therapeutics Ag | Use of anti-cd117 antibody drug conjugate (adc) |
| CN121712526A (zh) * | 2023-06-13 | 2026-03-20 | 辛瑟斯治疗股份有限公司 | 抗cd5抗体及其用途 |
| KR20250065477A (ko) * | 2023-11-03 | 2025-05-13 | 고려대학교 산학협력단 | 작용기 기능이 제거된 Fab-arm 교환 방지 Fc 변이체들 |
| WO2025099280A1 (en) * | 2023-11-08 | 2025-05-15 | Oxion Biologics Ab | Improved anti-ox40l antibodies |
| WO2026014615A1 (ko) * | 2024-07-10 | 2026-01-15 | 고려대학교 산학협력단 | 작용기 기능이 제거된 신규 당화 fc 변이체 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996040875A1 (en) * | 1995-06-07 | 1996-12-19 | Novartis Ag | Methods for obtaining compositions enriched for hematopoietic stem cells and antibodies for use therein |
| US7435596B2 (en) * | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| PT2099823E (pt) * | 2006-12-01 | 2014-12-22 | Seattle Genetics Inc | Agentes de ligação ao alvo variantes e suas utilizações |
| EP2625203A1 (en) * | 2010-10-05 | 2013-08-14 | Novartis AG | Anti-il12rbeta1 antibodies and their use in treating autoimmune and inflammatory disorders |
| PT3434767T (pt) * | 2010-11-30 | 2026-01-23 | Chugai Pharmaceutical Co Ltd | Agente terapêutico indutor de citotoxicidade |
| CN103649125A (zh) * | 2011-06-22 | 2014-03-19 | 霍夫曼-拉罗奇有限公司 | 利用包含mhc i类的复合物通过循环中的病毒特异性细胞毒性t细胞清除靶细胞 |
| CN104736174B (zh) * | 2012-07-06 | 2019-06-14 | 根马布私人有限公司 | 具有三重突变的二聚体蛋白质 |
| AU2013289883B2 (en) | 2012-07-13 | 2018-11-01 | Zymeworks Bc Inc. | Bispecific asymmetric heterodimers comprising anti-CD3 constructs |
| PL2880170T3 (pl) * | 2012-08-02 | 2017-02-28 | F.Hoffmann-La Roche Ag | SPOSÓB WYTWARZANIA ROZPUSZCZALNEGO FcR JAKO FUZJI Fc Z OBOJĘTNYM REGIONEM Fc IMMUNOGLOBULINY I JEGO ZASTOSOWANIA |
| KR102332303B1 (ko) * | 2013-05-31 | 2021-11-26 | 자임워크스 인코포레이티드 | 감소되거나 침묵화된 효과기 기능을 갖는 이종다량체 |
| JP6668345B2 (ja) * | 2014-11-21 | 2020-03-18 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 修飾された重鎖定常領域を含む抗体 |
| EP3268047B9 (en) * | 2015-03-09 | 2024-01-10 | Heidelberg Pharma Research GmbH | Amatoxin-antibody conjugates |
| US20190330335A1 (en) * | 2015-10-06 | 2019-10-31 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
| MA43389A (fr) * | 2015-12-02 | 2021-05-12 | Agenus Inc | Anticorps anti-ox40 et leurs procédés d'utilisation |
| WO2017106684A2 (en) | 2015-12-17 | 2017-06-22 | Janssen Biotech, Inc. | Antibodies specifically binding hla-dr and their uses |
| EP3912681A1 (en) * | 2016-03-14 | 2021-11-24 | Orega Biotech | Anti-cd39 antibodies |
| KR102692708B1 (ko) * | 2016-12-20 | 2024-08-07 | 에프. 호프만-라 로슈 아게 | 항-cd20/항-cd3 이중특이성 항체 및 4-1bb(cd137) 작용물질의 병용 요법 |
| KR20240093751A (ko) | 2016-12-21 | 2024-06-24 | 노파르티스 아게 | 조혈줄기세포를 제거하기 위한 항체 약물 접합체 |
| RU2755728C2 (ru) | 2016-12-23 | 2021-09-20 | Хайдельберг Фарма Ресёрч Гмбх | Новый конъюгат аманитина |
| CN111095521B (zh) * | 2017-10-24 | 2023-03-28 | 日本碍子株式会社 | 晶片载置台及其制法 |
| WO2019084057A2 (en) * | 2017-10-24 | 2019-05-02 | Magenta Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS |
| NZ781538A (en) * | 2019-04-24 | 2025-12-19 | Heidelberg Pharma Res Gmbh | Amatoxin antibody-drug conjugates and uses thereof |
| EP3958909A4 (en) * | 2019-04-24 | 2024-01-10 | Magenta Therapeutics, Inc. | ANTI-CD117 ANTIBODY DRUG CONJUGATES AND USES THEREOF |
| EP3959242A4 (en) * | 2019-04-24 | 2023-09-13 | Magenta Therapeutics, Inc. | ANTRACYCLINE ANTIBODY-DRUG CONJUGATES AND THEIR USES |
| JP2022531141A (ja) * | 2019-04-24 | 2022-07-06 | マジェンタ セラピューティクス インコーポレイテッド | 遺伝子治療のコンディショニング方法 |
| JP2022530443A (ja) * | 2019-04-24 | 2022-06-29 | マジェンタ セラピューティクス インコーポレイテッド | 抗ｃｄ１１７抗体薬物複合体およびその使用 |
| CN118131538A (zh) * | 2022-12-02 | 2024-06-04 | 群创光电股份有限公司 | 电子装置 |
-
2019
- 2019-10-23 AU AU2019366960A patent/AU2019366960A1/en active Pending
- 2019-10-23 CN CN201980081477.8A patent/CN113330026A/zh active Pending
- 2019-10-23 BR BR112021007555-0A patent/BR112021007555A2/pt not_active IP Right Cessation
- 2019-10-23 SG SG11202103568PA patent/SG11202103568PA/en unknown
- 2019-10-23 KR KR1020217015206A patent/KR20210081393A/ko active Pending
- 2019-10-23 EP EP19875208.1A patent/EP3873930A4/en active Pending
- 2019-10-23 JP JP2021518969A patent/JP7709376B2/ja active Active
- 2019-10-23 WO PCT/US2019/057741 patent/WO2020086776A1/en not_active Ceased
- 2019-10-23 CA CA3115680A patent/CA3115680A1/en active Pending
- 2019-10-23 MX MX2021004231A patent/MX2021004231A/es unknown
-
2020
- 2020-04-30 US US16/863,948 patent/US20200255523A1/en active Pending
-
2021
- 2021-04-13 IL IL282292A patent/IL282292A/en unknown
- 2021-05-13 CO CONC2021/0006259A patent/CO2021006259A2/es unknown
-
2025
- 2025-07-04 JP JP2025113503A patent/JP2025160215A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022512629A5 (https=) | ||
| JP2025160215A5 (https=) | ||
| JP2022553839A5 (https=) | ||
| ES2845924T3 (es) | Interruptores de células T con receptores de antígenos quiméricos peptídicos y usos de los mismos | |
| AU2021225125B9 (en) | Antibody drug conjugate loaded with binary toxins and its application | |
| AU2008247382B2 (en) | Anti-ICOS antibodies and their use in treatment of oncology, transplantation and autoimmune disease | |
| AU2010225951B2 (en) | Pharmaceutical formulation containing improved antibody molecules | |
| JP4879884B2 (ja) | 抗−ｉｌ−９抗体製剤及びその使用法 | |
| RU2461571C2 (ru) | Белки, связывающие il-12/p40 | |
| TWI616206B (zh) | 結合ｉｌ-４及／或ｉｌ-１３之抗體及其用途 | |
| ES2784131T3 (es) | Polipéptidos de unión beta del receptor PDGF | |
| JP6427789B2 (ja) | Ｃｌ２ａリンカーを有する抗体−ｓｎ−３８免疫複合体 | |
| RU2011140335A (ru) | Связывающие il-17 белки | |
| EP3958910A1 (en) | Anti-cd45 antibody drug conjugates and uses thereof | |
| JP2010159273A (ja) | 安定化された抗呼吸器合胞体ウイルス（ｒｓｖ）抗体製剤 | |
| CA3171709A1 (en) | T-cell bispecific binding proteins | |
| JP2016533335A5 (https=) | ||
| ES2909720T3 (es) | Terapia de combinación con un anticuerpo anti-CD19 y un análogo de purina | |
| JP2008527989A5 (https=) | ||
| CA3080547A1 (en) | Improved antibodies of the class igg4 | |
| US20220177577A1 (en) | Anti-cd117 antibody drug conjugates and uses thereof | |
| WO2020219775A1 (en) | Anti-cd117 antibody-drug conjugates and uses thereof | |
| US20220226493A1 (en) | Anthracycline antibody-drug conjugates and uses thereof | |
| JP2022531141A5 (https=) | ||
| JP2024510526A5 (https=) |